Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2132618 | 0.94 | S1PR1 (0.84) | S1PR1CYP2C9CYP2D6 | |
| SCHEMBL2133979 | 0.92 | S1PR1 (1.00) | S1PR1CYP2C9CYP2D6 | |
| SCHEMBL2134409 | 0.87 | S1PR1 (0.84) | S1PR1CYP2C9CYP2D6 | |
| SCHEMBL3421586 | 0.87 | S1PR1 (0.64) | S1PR1CYP2C9CYP2D6 | |
| SCHEMBL10268171 | 0.86 | S1PR1 (0.79) | S1PR1CYP2C9CYP2D6 | |
| SCHEMBL2410367 | 0.86 | S1PR1 (0.84) | S1PR1CYP2C9CYP2D6 | |
| SCHEMBL2136445 | 0.85 | S1PR1 (1.00) | S1PR1CYP2C9CYP2D6 | |
| SCHEMBL2132532 | 0.84 | S1PR1 (0.84) | S1PR1CYP2C9CYP2D6 | |
| SCHEMBL2137439 | 0.84 | S1PR1 (0.84) | S1PR1CYP2C9CYP2D6 | |
| SCHEMBL2137195 | 0.83 | S1PR1 (0.84) | S1PR1CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445891-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101134-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| WO-2010148649-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010148649-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101134-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR3 | S1PR1 1/4885CYP2C9 3708/4885CYP2D6 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.